Atorvastatin-modified dendritic cells in vitro ameliorate experimental autoimmune myasthenia gravis by up-regulated Treg cells and shifted Th1/Th17 to Th2 cytokines

Molecular and Cellular Neuroscience

Volumn 56, Issue , 2013, Pages 85-95

  Li, Xiao Li ^a   Liu, Ying ^a   Cao, Li Li ^a   Li, Heng ^a   Yue, Long Tao ^a   Wang, Shan ^a   Zhang, Min ^a   Li, Xiu Hua ^a   Dou, Ying Chun ^b   Duan, Rui Sheng ^a  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Atorvastatin; Cytokines; Dendritic cells; Experimental autoimmune myasthenia gravis; Treg cells

Indexed keywords

ATORVASTATIN; CD86 ANTIGEN; CHOLINERGIC RECEPTOR; CYTOKINE; IMMUNOGLOBULIN G ANTIBODY; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PEPTIDE; TRANSCRIPTION FACTOR FOXP3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; CD4+ CD25+ T LYMPHOCYTE; CELL MIGRATION; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; INGUINAL REGION; LYMPH NODE; LYMPHOCYTE PROLIFERATION; MONONUCLEAR CELL; MYASTHENIA GRAVIS; NONHUMAN; PRIORITY JOURNAL; RAT; REGULATORY T LYMPHOCYTE; SPLEEN; TH1 CELL; TH17 CELL; TH2 CELL; THYMUS; UPREGULATION;

ATORVASTATIN; CYTOKINES; DENDRITIC CELLS; EXPERIMENTAL AUTOIMMUNE MYASTHENIA GRAVIS; TREG CELLS;

ANIMALS; CELL PROLIFERATION; CYTOKINES; DENDRITIC CELLS; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HEPTANOIC ACIDS; IMMUNOTHERAPY; LYMPH NODES; MYASTHENIA GRAVIS, AUTOIMMUNE, EXPERIMENTAL; PYRROLES; RATS; RATS, INBRED LEW; SPLEEN; T-LYMPHOCYTES, HELPER-INDUCER; T-LYMPHOCYTES, REGULATORY; THYMUS GLAND; UP-REGULATION;

RATTUS;

EID: 84876402495     PISSN: 10447431     EISSN: 10959327     Source Type: Journal    
DOI: 10.1016/j.mcn.2013.03.005     Document Type: Article

References (56)

1. Aktas O., Waiczies S., Smorodchenko A., Dorr J., Seeger B., Prozorovski T., Sallach S., Endres M., Brocke S., Nitsch R., Zipp F. Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin. J. Exp. Med. 2003, 197:725-733.
2. Baggi F., Annoni A., Ubiali F., Milani M., Longhi R., Scaioli W., Cornelio F., Mantegazza R., Antozzi C. Breakdown of tolerance to a self-peptide of acetylcholine receptor alpha-subunit induces experimental myasthenia gravis in rats. J. Immunol. 2004, 172:2697-2703.
3. Baggi F., Antozzi C., Toscani C., Cordiglieri C. Acetylcholine receptor-induced experimental myasthenia gravis: what have we learned from animal models after three decades?. Arch. Immunol. Ther. Exp. (Warsz.) 2012, 60:19-30.
4. Banchereau J., Briere F., Caux C., Davoust J., Lebecque S., Liu Y.J., Pulendran B., Palucka K. Immunobiology of dendritic cells. Annu. Rev. Immunol. 2000, 18:767-811.
5. Boonyapisit K., Kaminski H.J., Ruff R.L. Disorders of neuromuscular junction ion channels. Am. J. Med. 1999, 106:97-113.
6. Cartwright M.S., Jeffery D.R., Nuss G.R., Donofrio P.D. Statin-associated exacerbation of myasthenia gravis. Neurology 2004, 63:2188.
7. Choi J., Hwang Y.K., Sung K.W., Lee S.H., Yoo K.H., Jung H.L., Koo H.H., Kim H.J., Kang H.J., Shin H.Y., Ahn H.S. Expression of Livin, an antiapoptotic protein, is an independent favorable prognostic factor in childhood acute lymphoblastic leukemia. Blood 2007, 109:471-477.
8. Duan R.S., Adikari S.B., Huang Y.M., Link H., Xiao B.G. Protective potential of experimental autoimmune myasthenia gravis in Lewis rats by IL-10-modified dendritic cells. Neurobiol. Dis. 2004, 16:461-467.
9. Duan R.S., Link H., Xiao B.G. Long-term effects of IFN-gamma, IL-10, and TGF-beta-modulated dendritic cells on immune response in Lewis rats. J. Clin. Immunol. 2005, 25:50-56.
10. Efuet E.T., Keyomarsi K. Farnesyl and geranylgeranyl transferase inhibitors induce G1 arrest by targeting the proteasome. Cancer Res. 2006, 66:1040-1051.
11. Evans M., Rees A. The myotoxicity of statins. Curr. Opin. Lipidol. 2002, 13:415-420.
12. Ferreira G.A., Teixeira A.L., Sato E.I. Atorvastatin therapy reduces interferon-regulated chemokine CXCL9 plasma levels in patients with systemic lupus erythematosus. Lupus 2010, 19:927-934.
13. + regulatory T cells in the steady state. J. Exp. Med. 2003, 198:737-746.
14. Furuzawa-Carballeda J., Vargas-Rojas M.I., Cabral A.R. Autoimmune inflammation from the Th17 perspective. Autoimmun. Rev. 2007, 6:169-175.
15. Greenwood J., Walters C.E., Pryce G., Kanuga N., Beraud E., Baker D., Adamson P. Lovastatin inhibits brain endothelial cell Rho-mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis. FASEB J. 2003, 17:905-907.
16. Hill M., Cuturi M.C. Negative vaccination by tolerogenic dendritic cells in organ transplantation. Curr. Opin. Organ Transplant. 2010, 15:738-743.
17. Jonuleit H., Schmitt E., Steinbrink K., Enk A.H. Dendritic cells as a tool to induce anergic and regulatory T cells. Trends Immunol. 2001, 22:394-400.
18. Kebir H., Kreymborg K., Ifergan I., Dodelet-Devillers A., Cayrol R., Bernard M., Giuliani F., Arbour N., Becher B., Prat A. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat. Med. 2007, 13:1173-1175.
19. Kim J.Y., Park K.D., Richman D.P. Treatment of myasthenia gravis based on its immunopathogenesis. J. Clin. Neurol. 2011, 7:173-183.
20. Kong Q.F., Sun B., Bai S.S., Zhai D.X., Wang G.Y., Liu Y.M., Zhang S.J., Li R., Zhao W., Sun Y.Y., Li N., Wang Q., Peng H.S., Jin L.H., Li H.L. Administration of bone marrow stromal cells ameliorates experimental autoimmune myasthenia gravis by altering the balance of Th1/Th2/Th17/Treg cell subsets through the secretion of TGF-beta. J. Neuroimmunol. 2009, 207:83-91.
21. Krueger T., Wohlrab U., Klucken M., Schott M., Seissler J. Autoantigen-specific protection of non-obese diabetic mice from cyclophosphamide-accelerated diabetes by vaccination with dendritic cells. Diabetologia 2003, 46:1357-1365.
22. Li X.L., Dou Y.C., Liu Y., Shi C.W., Cao L.L., Zhang X.Q., Zhu J., Duan R.S. Atorvastatin ameliorates experimental autoimmune neuritis by decreased Th1/Th17 cytokines and up-regulated T regulatory cells. Cell. Immunol. 2011, 271:455-461.
23. Li N., Mu L., Wang J., Zhang J., Xie X., Kong Q., Tang W., Yao X., Liu Y., Wang L., Wang G., Wang D., Jin L., Sun B., Li H. Activation of the adenosine A2A receptor attenuates experimental autoimmune myasthenia gravis severity. Eur. J. Immunol. 2012, 42:1140-1151.
24. Liu Y., Wang S., Shen L., Xu Y. Effects of simvastatin on the function of dendritic cells in patients with rheumatic arthritis. J. Huazhong Univ. Sci. Technol. Med. Sci. 2010, 30:741-745.
25. Maldonado R.A., von Andrian U.H. How tolerogenic dendritic cells induce regulatory T cells. Adv. Immunol. 2010, 108:111-165.
26. Maron D.J., Fazio S., Linton M.F. Current perspectives on statins. Circulation 2000, 101:207-213.
27. Mendoza-Coronel E., Camacho-Sandoval R., Bonifaz L.C., Lopez-Vidal Y. PD-L2 induction on dendritic cells exposed to Mycobacterium avium downregulates BCG-specific T cell response. Tuberculosis (Edinb.) 2011, 91:36-46.
28. Merx M.W., Liehn E.A., Janssens U., Lutticken R., Schrader J., Hanrath P., Weber C. HMG-CoA reductase inhibitor simvastatin profoundly improves survival in a murine model of sepsis. Circulation 2004, 109:2560-2565.
29. Milani M., Ostlie N., Wu H., Wang W., Conti-Fine B.M. CD4+ T and B cells cooperate in the immunoregulation of experimental autoimmune myasthenia gravis. J. Neuroimmunol. 2006, 179:152-162.
30. Mira E., Manes S. Immunomodulatory and anti-inflammatory activities of statins. Endocr. Metab. Immune Disord. Drug Targets 2009, 9:237-247.
31. Nahmod K.A., Vermeulen M.E., Raiden S., Salamone G., Gamberale R., Fernandez-Calotti P., Alvarez A., Nahmod V., Giordano M., Geffner J.R. Control of dendritic cell differentiation by angiotensin II. FASEB J. 2003, 17:491-493.
32. Negevesky G.J., Kolsky M.P., Laureno R., Yau T.H. Reversible atorvastatin-associated external ophthalmoplegia, anti-acetylcholine receptor antibodies, and ataxia. Arch. Ophthalmol. 2000, 118:427-428.
33. O'Garra A., Vieira P. Regulatory T cells and mechanisms of immune system control. Nat. Med. 2004, 10:801-805.
34. Oh S.J., Dhall R., Young A., Morgan M.B., Lu L., Claussen G.C. Statins may aggravate myasthenia gravis. Muscle Nerve 2008, 38:1101-1107.
35. Parmar B., Francis P.J., Ragge N.K. Statins, fibrates, and ocular myasthenia. Lancet 2002, 360:717.
36. Phillips P.S., Haas R.H., Bannykh S., Hathaway S., Gray N.L., Kimura B.J., Vladutiu G.D., England J.D. Statin-associated myopathy with normal creatine kinase levels. Ann. Intern. Med. 2002, 137:581-585.
37. Popov I., Li M., Zheng X., San H., Zhang X., Ichim T.E., Suzuki M., Feng B., Vladau C., Zhong R., Garcia B., Strejan G., Inman R.D., Min W.P. Preventing autoimmune arthritis using antigen-specific immature dendritic cells: a novel tolerogenic vaccine. Arthritis Res. Ther. 2006, 8:R141.
38. Purvin V., Kawasaki A., Smith K.H., Kesler A. Statin-associated myasthenia gravis: report of 4 cases and review of the literature. Medicine (Baltimore) 2006, 85:82-85.
39. Rizzo L.V., DeKruyff R.H., Umetsu D.T. Generation of B cell memory and affinity maturation. Induction with Th1 and Th2 T cell clones. J. Immunol. 1992, 148:3733-3739.
40. Romano E., Rossi M., Ratzinger G., de Cos M.A., Chung D.J., Panageas K., Wolchock J.D., Houghton A.N., Chapman P.B., Heller G., Yuan J., Young J.W. Peptide-loaded Langerhans cells, despite increased IL15 secretion and T cell activation in vitro, elicit anti-tumor T cell responses comparable to peptide-loaded monocyte-derived. Clin. Cancer Res. 2011, 17:1984-1997.
41. Sarkey J.P., Richards M.P., Stubbs E.B. Lovastatin attenuates nerve injury in an animal model of Guillain-Barre syndrome. J. Neurochem. 2007, 100:1265-1277.
42. Sato K., Nuki T., Gomita K., Weyand C.M., Hagiwara N. Statins reduce endothelial cell apoptosis via inhibition of TRAIL expression on activated CD4 T cells in acute coronary syndrome. Atherosclerosis 2010, 213:33-39.
43. Soltys J., Wu X. Complement regulatory protein Crry deficiency contributes to the antigen specific recall response in experimental autoimmune myasthenia gravis. J. Inflamm. (Lond.) 2012, 9:20.
44. Sun D., Fernandes G. Lovastatin inhibits bone marrow-derived dendritic cell maturation and upregulates proinflammatory cytokine production. Cell. Immunol. 2003, 223:52-62.
45. Tsakiri A., Tsiantoulas D., Frederiksen J., Svane I.M. Increased immunopotency of monocyte derived dendritic cells from patients with optic neuritis is inhibited in vitro by simvastatin. Exp. Neurol. 2010, 221:320-328.
46. Wang H.B., Shi F.D., Li H., van der Meide P.H., Ljunggren H.G., Link H. Role for interferon-gamma in rat strains with different susceptibility to experimental autoimmune myasthenia gravis. Clin. Immunol. 2000, 95:156-162.
47. -/- BALB/c mice suggests a pathogenic role of Th1 cells. J. Immunol. 2004, 172:97-103.
48. + regulatory T cells in human thymus. Nature 2005, 436:1181-1185.
49. Xiao B.G., Duan R.S., Link H., Huang Y.M. Induction of peripheral tolerance to experimental autoimmune myasthenia gravis by acetylcholine receptor-pulsed dendritic cells. Cell. Immunol. 2003, 223:63-69.
50. Yang H., Zhang Y., Wu M., Li J., Zhou W., Li G., Li X., Xiao B., Christadoss P. Suppression of ongoing experimental autoimmune myasthenia gravis by transfer of RelB-silenced bone marrow dentritic cells is associated with a change from a T helper Th17/Th1 to a Th2 and FoxP3+ regulatory T-cell profile. Inflamm. Res. 2010, 59:197-205.
51. Yarilin D., Duan R., Huang Y.M., Xiao B.G. Dendritic cells exposed in vitro to TGF-beta1 ameliorate experimental autoimmune myasthenia gravis. Clin. Exp. Immunol. 2002, 127:214-219.
52. Yilmaz A., Reiss C., Tantawi O., Weng A., Stumpf C., Raaz D., Ludwig J., Berger T., Steinkasserer A., Daniel W.G., Garlichs C.D. HMG-CoA reductase inhibitors suppress maturation of human dendritic cells: new implications for atherosclerosis. Atherosclerosis 2004, 172:85-93.
53. Yilmaz A., Reiss C., Weng A., Cicha I., Stumpf C., Steinkasserer A., Daniel W.G., Garlichs C.D. Differential effects of statins on relevant functions of human monocyte-derived dendritic cells. J. Leukoc. Biol. 2006, 79:529-538.
54. Yoon H.K., Lim J.Y., Kim T.J., Cho C.S., Min C.K. Effects of pravastatin on murine chronic graft-versus-host disease. Transplantation 2010, 90:853-860.
55. Zhang G.X., Xiao B.G., Bai X.F., van der Meide P.H., Orn A., Link H. Mice with IFN-gamma receptor deficiency are less susceptible to experimental autoimmune myasthenia gravis. J. Immunol. 1999, 162:3775-3781.
56. Zhang X., Jin J., Peng X., Ramgolam V.S., Markovic-Plese S. Simvastatin inhibits IL-17 secretion by targeting multiple IL-17-regulatory cytokines and by inhibiting the expression of IL-17 transcription factor RORC in CD4+ lymphocytes. J. Immunol. 2008, 180:6988-6996.